Controlling Off-Label Narcotics Usage - Impact of New Arizona Legislation ARS § 23-1062.02.

Slides:



Advertisements
Similar presentations
Independent External Review of Health Care Decisions in Vermont Department of Banking, Insurance, Securities and Health Care Administration.
Advertisements

Terminating a patient relationship When is it appropriate? According to the AMA's Code of Medical Ethics, Opinion 8.115, physicians have the option of.
Department of Arts and Culture Briefing on the Use of Official Languages Bill to the Select Committee on Education and Recreation Date:15 August 2012.
MAPS Michigan Automated Prescription System. Exempt From Reporting Medications administered directly to patients. Dispensing of up to a 48 hour supply.
Opioid Update F ederation of S tate M edical B oards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 F ederation.
WELCOME TO THE INDUSTRIAL COMMISSION SELF-INSURANCE SEMINAR.
Stimulant Prescribing Training Guide Completion of a ‘Notification of Treatment using Stimulant Medication’ form.
Open Records from the OAG Perspective Amanda Crawford Division Chief Open Records Division.
House Bill 2437 Health Carrier Access Payment Commissioner Kim Holland Oklahoma Insurance Department.
Sublingual Buprenorphine and Pain
Pain Management: a Regulatory Perspective William J. Schmidt, J.D. Senior Counsel, Investigations, Compliance & Enforcement Randy Beck Investigative Supervisor.
VIRGINIA PRESCRIPTION MONITORING PROGRAM C.A.R.E Presentation February 27, 2015 Ralph Orr Director, Virginia Prescription Monitoring Program.
WELCOME! DRUG TESTING TRAINING. PRE-TEST 1.Each State agency is required or not required to implement a drug testing policy. (Circle One) 2.Substance.
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 4 Prescription Writing.
Welcome Please set all cell phones to vibrate..
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
New Hire training.
2014 Legislative Session ASIA Legislative Agenda January 15, 2014.
Compensation for permanent impairment
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
Reimbursements, Reporting & Budget Modifications
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Prescription Drug Monitoring Programs: Analysis of State Level Usage Requirements Matthew Penn, JD, Carla Chen, JD Director, Public Health Law Program.
Pain Management And Prescribing Controlled Drugs Timothy J. Benedict, RPh Assistant Executive Director Ohio State Board of Pharmacy
Contractor Business Systems (CBS) Rule Eric Fassett.
FACT/FMIT Property and Casualty Overview Effective October 1, 2014.
April 15 th is not just the deadline for your taxes!!! Is your documentation complete for Pharmacist to Registered Technician Ratios? Policies.
Understanding and Using INCB Opioid Consumption Statistics: Including Morphine Equivalence 8 August 2012 Martha Maurer, MSW, MPH, PhD Pain & Policy Studies.
1 Roadmap to Timely Access Compliance Kristene Mapile, Staff Counsel Crystal McElroy, Staff Counsel Division of Licensing Department of Managed Health.
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade.
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
Impaired Physicians Harm Patients - Lose Licenses. Overview Definition Causes Warning Signs Treatment SHC Well-Being Committee Medical Board of California.
Chapter #07 Labor or work Discipline. Article 90 : Procedures for application of labor discipline Employees shall be obliged to follow the labor discipline.
 Established to provide the exclusive remedy for industrially injured employees, irrespective of fault.  Established to provide industrially injured.
John Lipovsky, MPPM, AREM, PMM
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
POST-ACCIDENT DRUG TESTING
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Excellent Public Schools Act of 2013 Instructional Collaboration Day II January 3, 2014.
60A-1, Fla. Admin. Code and Chapter 287, Florida Statutes Recurring Issues.
دکترارتین کمالی ثابتی ( متخصص پزشکی قانونی ومسمومیتها )
Office of Management and Enterprise Services Central Purchasing Division Keith Gentry Contract Manager
Georgia’s New and Improved PDMP. Greg Reybold, J.D. VP Public Policy & Association Counsel Georgia Pharmacy Association.
Safe Prescribing of Opioids for the Management of Chronic Nonterminal Pain La Tanya Austin, PGY3.
Maine Prescription Monitoring Program Using the PMP to Improve Patient Care John Lipovsky, MPPM, AREM, PMM Prescription Monitoring Program Coordinator.
Incidental Medical Services (IMS) Department of
April 15th is not just the deadline for your taxes
Legal and Regulatory Issues in Pain Management
Examining Potential Misuse of Gabapentin Among Patients Admitted to an Inpatient Behavioral Health Unit Samuel Kubas a, Pharm.D. Candidate 2018; Lucas.
Opioid Prescribing CAPT Thomas Weiser, MD, MPH Medical Epidemiologist
Probation Conditions for the WELLS CIRCUIT COURT
MWCC.MS.GOV  Services  Medical Fee Schedule
Pain Management and Worker’s Compensation
OPIOID SAFETY. Indiana Statistics In Summary… About 100 Hoosiers die from drug overdoses every month, many from opioids such as heroin and prescription.
The Physician Payments Sunshine Act
Confidential Records and Protected Disclosures
Patient Confidentiality: Drug Alert Systems
Prescription Drug Monitoring Program
2019 Medicare Part D Rule Opioid-related Provisions
Prescription Drug Monitoring Program
TRTR Briefing September 2013
National Credentialing Forum 2019 San Diego, CA February
VSDP Employer Support Training Short-Term Disability and Long-Term Disability Management January 2019.
Proposed Commission Rules Changes WCLA 10/20/16
The Silent Killer in America
Pain Management JEFFREY TAN HO, D.O.
Presentation transcript:

Controlling Off-Label Narcotics Usage - Impact of New Arizona Legislation ARS §

Off-label prescription of controlled substances; prescription of schedule II controlled substances; reports; treatment plans; definition A. On written request of an interested party as defined in section , a physician shall include in the report required under commission rule information pertaining to the off-label use of a narcotic, opium based controlled substance or schedule II controlled substance by a claimant, which may include the justification for use of the controlled substance, and a treatment plan that includes a description of measures that the physician will implement to monitor and prevent the development of abuse, dependence, addiction or diversion by the employee. The interested party may also request that the treatment plan include a medication contract, a plan for subsequent follow-up visits and drug testing and documentation that the medication regime is providing relief that is demonstrated by improved function. B. If the physician does not comply with this section, the interested party is not responsible for payment for the physician's services until the physician complies with subsection A of this section. C. For the purposes of this section, "off-label use" means use of a prescription medication by a physician to treat a condition other than the use for which the drug was approved by the United States food and drug administration.

Commonly prescribed narcotics that constitute “Off-Label” use: ◦ Fentanyl based drugs –  Actiq  Duragesic  Fentora “ACTIQ is an opioid analgesic indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients must remain on around-the-clock opioids when taking ACTIQ.” ◦ Label approved by FDA on 11/09/09

Initial letter to physicians: Dear Dr. _________: As part of SCF’s efforts to implement the provisions of A.R.S. § , a review of this claim reveals that you have been prescribing the following drugs to the above-referenced injured worker:____________________ As you know, these drugs are narcotic, opium based controlled substance or schedule II controlled substances, and our medical review indicates that the drug(s) are being prescribed in a manner inconsistent with the indications and usage as approved by the United States Food and Drug Administration. Pursuant to A.R.S. § , it is requested that you provide the following information in your next monthly report, as required by Industrial Commission Rule A.A.C. R (“Physician’s Duty to Provide Signed Reports”): Your justification for use of the controlled substance. A treatment plan that includes a description of measures that you will implement to monitor and prevent the development of abuse, dependence, addiction or diversion by the injured worker. We request that you require the injured worker to sign a medication contract (the same or similar to the enclosed sample) and that you assure compliance with the contract. Your plan for subsequent follow-up visits and drug testing (at SCF Arizona’s expense). Documentation that the medication regime is providing relief that is demonstrated by improved function, either through an ability to return to work, or if unable to work, an improved ability to perform normal daily activities. We appreciate your attention to this request. Should you have any questions, please do not hesitate to contact me.

Follow-up letter to non-compliant physicians Dear Dr. ________________: On ____date___, you were sent a letter requesting information regarding the continued prescription of drugs to the above-referenced injured workers (copy enclosed). Pursuant to A.R.S. § and Industrial Commission Rule A.A.C. R , you are required to provide this information in your monthly signed report. To date, I have not received your report. Please be advised that if I do not receive the requested information within 10 business days, I will be forced to deny further payment for your services, as permitted pursuant to the statute. Thank you for your prompt attention to this matter.

High doses as “off-label” use We have reviewed the prescription history of the above-referenced injured worker as a part of SCF's efforts to implement the provisions of A.R.S. § It appears that this injured worker has a daily opioid intake exceeding 120 mg MED (morphine equivalent dose). In some cases, such high-dose therapy is not needed to treat moderate to severe pain, and can even be counterproductive. Recent medical literature suggests that patients with a daily intake in excess of 120 mg MED should be more closely evaluated, and the chronic use of opioids has actually been linked to heightened pain sensitivity. For these reasons, prescribing this patient medications in such high doses may be inconsistent with the indications and usage as approved by the United States Food and Drug Administration. Therefore, in accordance with A.R.S. § , it is requested that you provide the following information in your next monthly report, as required by the Industrial Commission Rule A.A.C. R ("Physician's Duty to Provide Signed Reports"):

Results after one year of /1/2009 to 12/31/2009 – 28 claimants receiving fentanyl drugs off label at an annual cost of $717K. Statute effective date September /1/2010 thru 8/30/2010 – Total drug cost $30K As of 8/30/2010 – 2 claimants on fentanyl drugs at cost of $7K

Increasing the scope of – potential 2011 legislative amendments Broaden application to all Class II narcotics or controlled substances (medical marijuana?) Set dosage threshold for physician mandatory reporting: 120 MED (morphine equivalent dose) Create presumption of unprofessional conduct by physician for medical board disciplinary action for failure to comply with statute Create right of carrier to request change of physicians for physician noncompliance Immunity against bad faith if carrier acts consistently with statute Exception to res judicata to allow review of prior awards

Questions?